There have been significant developments in genome editing technology over the past few years, particularly the new ‘CRISPR’ technology, which significantly increases safety and efficacy. There has been immense uptake of the technology in research, with publications noting CRIPR in the methods steadily increasing. Therapeutic applications of CRISPR are becoming a reality, and germline applications are also on the horizon, raising concerns about ethical, legal and social implications. We are also concerned about embryo research in this context and how it plays into genome editing research and use.
The CLG continues its research on how to assist the development of promising genetic technologies while ensuring safety to the public. It builds on much of our research in the areas of Personalised Medicine and Commercialisation of Biotechnology in particular.
To kick off our research in this area, we hosted a workshop on the topic.